ACT Brief: New CAR-T Trial Requirements, Pfizer Advances Oral GLP-1 Strategy, and Kisqali Shows Durable Long-Term Control

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• The FDA has introduced a significant shift in its expectations for future CAR-T approvals, outlining that new therapies will generally need to demonstrate superiority to standard treatments in randomized trials rather than relying on single-arm designs. Earlier this year, the agency eliminated REMS reporting requirements for approved CAR-Ts, reducing administrative and logistical burdens for treatment centers while shortening monitoring periods for patients—changes that will meaningfully influence trial design, evidence generation, and operational planning across the cell therapy landscape.
• Pfizer announced an exclusive global collaboration and license agreement with Yao Pharma for YP05002, an oral small-molecule GLP-1 agonist currently in Phase I for chronic weight management. Under the agreement, Yao will complete its ongoing early-phase studies, while Pfizer assumes global development, manufacturing, and commercialization—strengthening the company’s expanding cardiometabolic pipeline and positioning the asset for potential combination strategies within its broader obesity portfolio.
• And as new clinical data continue to shape long-term expectations in oncology, a pooled analysis of MONALEESA trials presented at the San Antonio Breast Cancer Symposium shows that roughly one in four patients on first-line Kisqali achieve disease control beyond four years. The findings reinforce Kisqali role as a cornerstone therapy in HR+/HER2– advanced breast cancer while underscoring the need for resourcing models that accommodate longer treatment durations and sustained follow-up in modern oncology programs.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.